{"id":"sintilimab-combined-with-docetaxel-monotherapy","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, sintilimab enhances the body's immune response against cancer cells, leading to their destruction. This mechanism is particularly effective in treating various types of cancer. Sintilimab, when combined with docetaxel, has shown promising results in clinical trials.","oneSentence":"Sintilimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:14.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Non-small cell lung cancer, PD-L1 negative"}]},"trialDetails":[{"nctId":"NCT07016737","phase":"PHASE3","title":"Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Ye jinjun","startDate":"2024-08-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":79},{"nctId":"NCT04144582","phase":"PHASE2","title":"Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Yongchang Zhang","startDate":"2019-01-01","conditions":"Non-small Cell Lung Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sintilimab Combined With Paclitaxel Monotherapy","Sintilimab Combined With Irinotecan Monotherapy","Camrelizumab Combined With Docetaxel Monotherapy","Camrelizumab Combined With Paclitaxel Monotherapy","Camrelizumab Combined With Irinotecan Monotherapy"],"phase":"phase_3","status":"active","brandName":"Sintilimab Combined With Docetaxel Monotherapy","genericName":"Sintilimab Combined With Docetaxel Monotherapy","companyName":"Ye jinjun","companyId":"ye-jinjun","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sintilimab is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells. Used for Non-small cell lung cancer, PD-L1 positive, Non-small cell lung cancer, PD-L1 negative.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}